Every article, presentation, spotlight, and news item we've tagged to Hallmarks of Aging.
Showing 97–120 of 225
Iron accumulation drives a coordinated aging process termed ferro-aging, characterized by oxidative damage and cellular senescence across tissues. Vitamin C administration reversed aging markers and restored functional capacity in aged cynomolgus monkeys, suggesting a tractable intervention point in iron-dependent aging pathways.
The Senotherapeutics Biomarker Consortium addresses a critical gap in senescence measurement standards across academia, industry, and regulators. Standardized biomarkers are essential to advance clinical translation of senotherapeutic interventions, as current measurement heterogeneity impedes trial reproducibility and regulatory confidence.
Iron accumulation drives a coordinated aging process called ferro-aging through oxidative damage and lipid peroxidation; vitamin C reverses these markers in primate models. This identifies iron metabolism and lipid oxidation as actionable targets in cellular senescence.
ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.
The extracellular matrix—the structural scaffold surrounding reproductive tissues—undergoes progressive degradation during female reproductive aging, compromising ovarian function and fertility. Targeting matrix preservation and remodeling represents a mechanistic approach to extending reproductive lifespan and potentially supporting broader aging-related outcomes.
Succinate dehydrogenase (SDH), a mitochondrial enzyme, becomes overactive in aging T cells and drives an age-related shift toward Th17 inflammatory responses. Inhibiting SDH in older adults' T cells reduces proinflammatory cytokine production, while restoring succinate levels in younger T cells reproduces the inflammatory profile seen in aging.
Aging drives accumulation of a distinct CD8 T cell population lacking CXCR3 that exhibits Th2-skewed transcriptional and epigenetic programming. This shift correlates with increased risk for asthma, chronic liver disease, and type 2 diabetes, suggesting age-related immune dysregulation follows a predictable molecular trajectory.
Evolutionary theory predicts that organisms should invest in rejuvenation when it is energetically favorable, yet most do not. This paradox reveals fundamental constraints on aging that challenge current models of senescence and suggests the biological capacity for rejuvenation may be far more limited than previously assumed.
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Methylmalonic acid accumulates in aging intervertebral discs and drives degeneration through pathological vascularization via the CCL7/JAK2-STAT3/VEGF signaling pathway. VEGF receptor inhibition slowed disc degeneration in preclinical models, establishing vascularization as a therapeutic target in disc disease.
Overexpression of somatostatin, a neuropeptide normally produced by neurons, reduces microglial activation and amyloid-β burden while improving cognitive function in an Alzheimer's disease mouse model. The finding identifies a previously untested communication pathway between neurons and immune cells that becomes dysregulated in the disease and offers a target for existing pharmaceuticals.
T cells retain pro-inflammatory characteristics long after weight loss, perpetuating immune dysregulation in previously obese individuals. This 'obesity memory' may persist for years in humans despite normalization of body mass, suggesting that metabolic recovery and immune recovery operate on different timelines.
Exosomes in the gut lumen change composition with age, with those from older mice directly impairing barrier integrity and insulin sensitivity in younger recipients, while young exosomes reverse these effects in older mice. This identifies a specific molecular mechanism linking intestinal barrier dysfunction to metabolic aging.
Vascular injury triggers rapid nuclear deformation in arterial smooth muscle cells, accelerating cellular senescence through prelamin A accumulation. Zinc supplementation partially restores normal nuclear morphology by supporting the enzyme Zmpste24, which processes this senescence-driving protein.
Preclinical Parkinson's research has relied on young animal models and acute toxin paradigms that fail to capture the disease's age-dependent biology. The PD-AGE roadmap calls for aging-integrated models—using genetic systems with gradual phenotypes and crossing them with accelerated aging strains—to better reflect how Parkinson's actually develops in older humans and improve translational reliability.
Somatic mutations accumulating in microglia—brain immune cells—correlate with Alzheimer's disease pathology and cognitive decline. These acquired genetic variants, distinct from inherited risk factors, represent a previously underappreciated mechanism driving neurodegeneration and suggest new intervention points before symptomatic disease emerges.
Dendritic cell migration from the gut declines with age, impairing vaccine response. Oral delivery of yeast-derived nanoparticles restores this migration pathway and vaccine efficacy in aged mice, pointing to a specific mechanism by which immune function deteriorates and can be supported.
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
Chromosomal passenger complex proteins show age-dependent dysregulation in the uterus during implantation and decidualization in aging female mice, with reduced cell proliferation markers and altered protein expression patterns that correlate with reduced implantation success. These findings identify a cellular mechanism underlying age-related fertility decline independent of ovarian function.
Vesalic's discovery identifies a systemic metabolic dysfunction marked by altered lipid composition in circulating extracellular vesicles in ALS patients' blood. This reframes neurodegenerative diseases as downstream consequences of upstream metabolic abnormalities rather than purely neurological conditions localized to the brain, with implications for earlier detection and intervention across multiple neurodegenerative pathologies.
Senescent cells drive postpartum mammary gland involution and tissue remodeling, but simultaneously create a microenvironment permissive to tumor initiation. This reveals how a tissue repair mechanism can paradoxically increase cancer risk during a critical metabolic transition.
Visceral adipose tissue accumulation in midlife correlates with metabolic dysfunction, but the relationship is contextual rather than categorical. The review identifies conditions under which visceral fat becomes pathogenic and describes interventions to mitigate harm.
Local radiation injury triggers a cascade in which damaged skin cells release eccDNA, activating immune signaling in the spleen that produces hyperactive neutrophils expressing high levels of galectin-9. These neutrophils infiltrate multiple organs, disrupt bone marrow function, and drive sustained immune dysregulation that accelerates frailty—a finding that identifies a specific mechanistic pathway underlying radiation-induced aging and functional decline.
Lysoway Therapeutics has initiated Phase 1 testing of LW-1017, a small-molecule TRPML1 agonist designed to restore autophagy-lysosomal function in neurodegenerative diseases including Alzheimer's and Parkinson's. The compound represents a potential intervention targeting cellular waste clearance mechanisms that decline with age.
